Astellas Announces Continuation of Performance-linked Stock Compensation Scheme

Tokyo, May 15, 2017—Astellas Pharma Inc. (TSE:4503; President and CEO: Yoshihiko Hatanaka, hereinafter, the “Company”) announced that at the meeting of the Board of Directors held today a resolution was passed for the Incentive Plan (hereinafter, the “Plan”) which will be implemented in fiscal year 2017 based on the Performance-linked Stock Compensation Scheme (hereinafter the “Scheme”) introduced in fiscal year 2015, as described below.

1. Objective for the Scheme

(1) Since fiscal year 2015, the Company has introduced the Scheme for Directors and Corporate Executives (excluding outside Directors, and Directors and Corporate Executives residing overseas; hereinafter collectively referred to as “Directors and Other Executives”) for the purpose of increasing their awareness of contributing to the sustainable growth in business results and corporate value. The Scheme is the medium-to long-term incentive-based compensation plan that is highly transparent and objective and closely linked with the Company’s business results.

(2) The Scheme employs a framework referred to as the executive compensation BIP (Board Incentive Plan) trust (hereinafter “BIP Trust”). BIP Trust is an executive incentive plan modeled on Performance Share and Restricted Stock systems in the U.S. The BIP Trust acquires the Company’s shares and conducts a “delivery of the Company’s shares” (as set forth in 3. (5) below; hereinafter the same) to the Directors and Other Executives based on the level of attainment of the medium-term management targets. (*1) (*2)

(*1) Compensation of Directors and Other Executives consists of “basic remunerations,” “bonuses” and “stock compensation.” Additionally, compensation of outside Directors and Corporate Auditors who are independent from business execution is only “basic remunerations.”

(*2) The Company has established a Compensation Committee, which is chaired by an outside Director and in which the majority of the members are outside Directors, as an advisory body to the Board of Directors. Through the deliberation by the Compensation Committee of the introduction of the Scheme, the Company has ensured the transparency and objectivity of the decision-making process for the compensation system.
2. The Structure of the BIP Trust

1) Based on the Scheme, the Company will resolve on the implementation and content of the Plan for fiscal year 2017 at the meeting of the Board of Directors.

2) The Company will entrust money, and establish a trust with the Company's Directors who have satisfied the beneficiary conditions as beneficiaries ("BIP Trust A") and a trust with the Company's Corporate Executives who have satisfied the beneficiary conditions as beneficiaries ("BIP Trust B") (Hereinafter BIP Trust A and BIP Trust B will collectively be referred to as "the Trust"). The money entrusted in BIP Trust A will be within the scope of approval of the 10th Term General Meeting of Shareholders.

3) The Trust, in accordance with the instructions of the trust administrator, will use the money entrusted in 2) to acquire the Company's shares on the stock market.

4) Dividends for the Company's shares in the Trust will be paid in the same way as with other shares of the Company.

5) Voting rights are not to be exercised on the Company's shares within the Trust throughout the trust period.

6) During the trust period, beneficiaries will receive delivery of the Company's shares in accordance with the Company's Share Delivery Policy.

7) In the event that residual shares remain at the expiration of the trust period as a result of the management targets not being met during the trust period or other reasons, the Trust will continue to be used as an incentive plan based on the Scheme by making changes to the trust agreement and additional entrustments, or a gratis transfer of these residual shares will be made from the Trust to the Company and upon acquiring these shares the Company plans to implement the cancellation of them by resolution of the Board of Directors.

8) Upon conclusion of the Trust, the residual assets remaining after allocation to the beneficiaries are to belong to the Company within the scope of the reserve fund for trust expenses after deductions for stock purchases from trust money. In the event that there remain residual assets beyond the scope of the reserve fund for trust expenses, such assets are to be donated to an organization having no relationship of interest with the Company or executives of the Company.
3. Details of the Plan

(1) Overview of the Plan
The Plan is an incentive plan, under which delivery of the Company’s shares will be conducted as executive compensation during the three-year period from the fiscal year ending March 31, 2018 to the fiscal year ending March 31, 2020 (hereinafter the “Applicable Period”), according to the level of attainment of medium-term management targets and other criteria throughout the Applicable Period.

The Company intends to continue implementing incentive plans which are similar to the Plan each year in and after the following fiscal year by establishing new BIP Trusts or by making changes or additional entrustments to the existing BIP Trusts that have expired. The details of the incentive plans to be implemented in and after the following fiscal year will be determined by resolution of the Board of Directors in each case. With respect to the incentive plans to be implemented in and after the following fiscal year, the money to be entrusted to the incentive plan based on BIP Trust A and the delivery of the Company’s shares relating to BIP Trust A will be within the scope approved by the 10th Term General Meeting of Shareholders.

(2) Individuals eligible under the Plan (Beneficiary Conditions)
As a general rule, Directors and Other Executives who are in office as of July 1, 2017 (hereinafter “Eligible Individuals”), if they meet the following beneficiary conditions, shall receive delivery of the Company’s shares from the Trust, in accordance with (4) below.

The beneficiary conditions are as follows:
1) such person shall continue to serve as Director (excluding outside Directors) with respect to BIP Trust A and as Corporate Executive with respect to BIP Trust B until June 1, 2020;
2) such person shall reside in Japan; and
3) such person shall have met other criteria which are deemed necessary for achieving the purpose of the stock compensation scheme.

(3) Trust period
The trust period shall be from May 19, 2017 (planned) to August 31, 2020 (planned). At the expiration of the trust period, the Company may continue the Trust in the form of incentive plans which are similar to the Plan by making changes to the trust agreement and additional entrustments.

(4) Number of the Company’s shares to be delivered to Eligible Individuals
The number of the Company’s shares to be delivered to Eligible Individuals (including the number of the Company’s shares to be converted into cash in accordance with (5) below) shall be determined on the basis of the points, which have been allocated in accordance
with the following, with 1 point corresponding to 1 share of the Company’s share (*3).

(*3) In the event that the number of the Company’s shares belonging to the Trust increases or decreases due to stock split, gratis allotment or stock consolidation, etc., the number of the Company’s shares to be delivered per point shall be adjusted by means of a reasonable method.

Basic points shall be allocated to the Eligible Individuals who are in office as of July 1, 2017 in accordance with the following formula.

(Formula for the calculation of basic points)
Basic amount determined based on rank (*4) ÷ Average closing price of the Company’s shares on TokyoStock Exchange for June 2017
* Any fractions of less than one shall be discarded.

(*4) The basic amount levels shall be determined based on the contents of business execution and the responsibilities of each individual, as well as by considering a balance with other monetary compensation, etc., to function soundly as the medium- to long-term incentive plan.

Eligible Individuals who are in office as of June 1, 2020 shall receive delivery of the Company’s shares from the Trust in numbers corresponding to the points calculated according to the formula below.

Basic points × Performance-linked coefficient (*5)
* Any fractions of less than one shall be discarded.

(*5) The performance-linked coefficient shall be determined within a range of 0 to 200% based on the level of attainment of the pre-determined, consolidated management targets for sales, core operating profit ratio and core ROE (core profit for the year / equity) for the fiscal year ending March 31, 2020. Evaluation of the level of attainment of management targets shall be reported to and determined by the Board of Directors after deliberation by the Compensation Committee.

(5) Method and period for delivering the Company’s shares to Directors and Other Executives
“Delivery of the Company’s shares” refers to, at a given time, the receipt of half of the number of the Company’s shares corresponding to the allocated points from the Trust (provided that shares less than one unit shall be converted into cash within the Trust and the cash equivalent to the amount of conversion will be received), and the receipt of the cash equivalent to the remaining half after conversion into cash within the Trust.
Eligible Individuals who have met the beneficiary conditions shall receive delivery of the Company’s shares around June 2020.
In the event that an Eligible Individual retires during the trust period (excluding voluntary retirement and dismissal), as a general rule, such individual shall receive the delivery of the Company’s shares in numbers corresponding to the points that have been allocated up to the time of retirement.
In the event that an Eligible Individual becomes deceased during the trust period, as a
general rule, the Company’s shares shall be converted into cash in numbers corresponding
to the points which have been allocated to such individual up to that time within the Trust,
and the cash equivalent to the amount of conversion shall be received by such individual’s
heir from the Trust.

(6) Amount expected to be entrusted to BIP Trust A and the number of the Company’s shares
expected to be delivered from the Trust (including the number of the Company’s shares to
be converted into cash in accordance with (5) above).

The Company intends to entrust ¥202 million to BIP Trust A (*6).

(*6) Equivalent to the total amount of funds required by the Trust to acquire shares, trust fees and trust
expenses during the trust period. At the 10th Term General Meeting of Shareholders, the Scheme for
Directors was approved subject to the amount of contribution to the Scheme being limited to ¥350 million
per fiscal year. The amount that may be entrusted by the Company to the Scheme in each fiscal year will
be within the amount resolved by the 10th Term General Meeting of Shareholders.

The maximum number of the Company’s shares to be delivered by BIP Trust A during the
trust period in accordance with (4) above shall be the number derived by dividing the
money entrusted to BIP Trust A by the average closing price of the Company’s shares on
Tokyo Stock Exchange for June 2017.

(7) Method for acquiring the Company’s shares by the Trust
The acquisition of the Company’s shares by the Trust is planned to be made on the stock
market.

(8) Exercise of voting rights of the Company’s shares within the Trust
In order to maintain a neutral position vis-a-vis management, no voting rights shall be
exercised on the Company’s shares within the Trust during the trust period.

(9) Handling of dividends on the Company’s shares within the Trust
Dividends on the Company’s shares within the Trust shall be received by the Trust and
applied to trust fees and trust expenses for the Trust.

(10) Handling at the expiration of the trust period
In the event that residual shares remain at the expiration of the trust period due to the
management targets not being met during the Applicable Period or other reasons, the
Company may continue the Trust in the form of incentive plans which are similar to the Plan
by making changes to the trust agreement and additional entrustments. If the Trust is to be
terminated due to the expiration of the trust period, gratis transfer of these residual shares will
be made from the Trust to the Company, and upon acquiring these shares the Company
plans to implement the cancellation of them by resolution of the Board of Directors.

Additionally, in the event that residual dividends on the Company’s shares within the Trust remain at the expiration of the trust period and the Company continues to use the Trust, such residual assets shall be applied towards the acquisition of shares. However, if the Company concludes the Trust due to the expiration of the trust period, such assets are planned to be donated to an organization having no relationship of interest with the Company or executives of the Company.
### Contents of the Trust Agreement to be concluded in fiscal year 2016

<table>
<thead>
<tr>
<th></th>
<th>“BIP Trust A”</th>
<th>“BIP Trust B”</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Trust category</td>
<td>Monetary trust other than a specific individually operated monetary trust</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(third-party benefit trust)</td>
</tr>
<tr>
<td>2</td>
<td>Trust objective</td>
<td>To provide incentive to the Directors of the Company</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To provide incentive to the Corporate Executives of the Company</td>
</tr>
<tr>
<td>3</td>
<td>Trustor</td>
<td>The Company</td>
</tr>
<tr>
<td>4</td>
<td>Trustee</td>
<td>Mitsubishi UFJ Trust and Banking Corporation (planned)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Joint Trustee: The Master Trust Bank of Japan, Ltd.)</td>
</tr>
<tr>
<td>5</td>
<td>Beneficiaries</td>
<td>The Company’s Directors who have met beneficiary conditions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Company’s Corporate Executives who have met beneficiary conditions</td>
</tr>
<tr>
<td>6</td>
<td>Trust administrator</td>
<td>Third party with no relationship of interest with the Company (Certified</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Public Accountant)</td>
</tr>
<tr>
<td>7</td>
<td>Date of trust agreement</td>
<td>May 19, 2017 (planned)</td>
</tr>
<tr>
<td>8</td>
<td>Trust period</td>
<td>May 19, 2017 (planned) to August 31, 2020 (planned)</td>
</tr>
<tr>
<td>9</td>
<td>Start of the Plan</td>
<td>July 1, 2017 (planned)</td>
</tr>
<tr>
<td>10</td>
<td>Exercise of voting rights</td>
<td>Not to be exercised</td>
</tr>
<tr>
<td>11</td>
<td>Type of shares to be acquired</td>
<td>Common stock of the Company</td>
</tr>
<tr>
<td>12</td>
<td>Amount of entrustment</td>
<td>¥202million (planned) (Including trust fees and trust expenses)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¥525million (planned) (Same as on the left)</td>
</tr>
<tr>
<td>13</td>
<td>Acquisition period of shares</td>
<td>May 23, 2017 (planned) to May 31, 2017 (planned)</td>
</tr>
<tr>
<td>14</td>
<td>Method of acquiring shares</td>
<td>Acquisition on the stock market</td>
</tr>
<tr>
<td>15</td>
<td>Rights holder</td>
<td>The Company</td>
</tr>
<tr>
<td>16</td>
<td>Residual assets</td>
<td>The Company, the rights holder, shall receive residual assets within the</td>
</tr>
<tr>
<td></td>
<td></td>
<td>scope of the reserve fund for trust expenses after deductions for stock</td>
</tr>
<tr>
<td></td>
<td></td>
<td>purchases from trust money</td>
</tr>
</tbody>
</table>

[Administrative tasks related to the trust and shares]

1) Administrative tasks related to the trust:
   Mitsubishi UFJ Trust and Banking Corporation is to handle trust-related administrative tasks as the Trust’s trustee.

2) Administrative tasks related to the shares:
   Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. is to handle administrative tasks related to delivering the Company’s shares to beneficiaries based on an administration entrustment agreement.
About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473